Adverse effects of antiepileptic drugs

被引:95
作者
Perucca, E
Meador, KJ
机构
[1] Univ Pavia, Dept Internal Med & Therapeut, Clin Pharmacol Unit, I-27100 Pavia, Italy
[2] IRCCS S Mondino Fdn, Lab Diagnost & Appl Biol Res, Inst Neurol, Pavia, Italy
[3] Univ Florida, Dept Neurol, Gainesville, FL USA
来源
ACTA NEUROLOGICA SCANDINAVICA | 2005年 / 112卷
关键词
adverse effects; antielpileptic drugs; drug treatment; epilepsy;
D O I
10.1111/j.1600-0404.2005.00506.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Adverse effects of antiepileptic drugs (AEDs) are common, can have a considerable impact on quality of life and contribute to treatment failure in up to 40% of patients. The adverse effect profiles of AEDs differ greatly and are often a determining factor in drug selection because of the similar efficacy rates shown by most AEDs. The most common adverse effects are dose dependent and reversible. Cognitive impairment is of particular concern, especially for patients who work or study. Idiosyncratic effects, such as skin rashes, and chronic effects, such as weight gain, can lead to high rates of treatment discontinuation and complicate clinical management. Nearly all conventional AEDs increase the risk of congenital malformations when taken during pregnancy, with valproate posing a potentially greater risk, whereas the potential teratogenicity of new generation AEDs is largely unknown. Most conventional AEDs have a poor record when it comes to drug interactions, largely because of their tendency to interfere wit hepatic drug metabolism. Some newer AEDs have no effect on hepatic drug metabolizing enzymes and are renally excreted, resulting in a lower potential for drug interactions. However, further research is needed to confirm the apparent improvement in tolerability offered by some of the newer AEDs.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 55 条
[1]   A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures [J].
Aldenkamp, AP ;
Baker, G ;
Mulder, OG ;
Chadwick, D ;
Cooper, P ;
Doelman, J ;
Duncan, R ;
Gassmann-Mayer, C ;
de Haan, GJ ;
Hughson, C ;
Hulsman, J ;
Overweg, J ;
Pledger, G ;
Rentmeester, TW ;
Riaz, H ;
Wroe, S .
EPILEPSIA, 2000, 41 (09) :1167-1178
[2]  
[Anonymous], 2004, PAT MIND SURV COGN F
[3]   Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures [J].
Arroyo, S ;
Anhut, H ;
Kugler, AR ;
Lee, CM ;
Knapp, LE ;
Garofalo, EA ;
Messmer, S .
EPILEPSIA, 2004, 45 (01) :20-27
[4]   Life-threatening adverse events of antiepileptic drugs [J].
Arroyo, S ;
de la Morena, A .
EPILEPSY RESEARCH, 2001, 47 (1-2) :155-174
[5]   Commission on outcome measurement in epilepsy, 1994-1997: Final report [J].
Baker, GA ;
Camfield, C ;
Camfield, P ;
Cramer, JA ;
Elger, CE ;
Johnson, AL ;
da Silva, AM ;
Meinardi, H ;
Munari, C ;
Perucca, E ;
Thorbecke, R .
EPILEPSIA, 1998, 39 (02) :213-231
[6]  
BATTINO D, 2000, MEYLERS SIDE EFFECTS, P164
[7]  
Biton V, 2001, ANN PHARMACOTHER, V35, P173
[8]   Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy [J].
Brodie, MJ ;
Overstall, PW ;
Giorgi, L .
EPILEPSY RESEARCH, 1999, 37 (01) :81-87
[9]  
Craig JJ, 2004, EPILEPSIA, V45, P229
[10]   Lamotrigine and the risk of malformations in pregnancy [J].
Cunnington, M ;
Tennis, P .
NEUROLOGY, 2005, 64 (06) :955-960